Economic evaluation of the impact of nicorandil in angina (IONA) trial.

Heart
A WalkerI Ford

Abstract

To estimate the net cost of adding nicorandil to usual treatment for patients with angina and to compare this with indicators of health benefit. Cost effectiveness analysis. Based on results of the IONA (impact of nicorandil on angina) trial. Patients with angina fulfilling the entry criteria for the IONA trial. In one arm of the trial nicorandil was added to existing antianginal treatment and compared with existing treatment alone. Costs were for use of hospital resources (for cardiovascular, cerebrovascular, and gastrointestinal reasons), nicorandil, and care after hospital discharge. Benefits were assessed in three ways: (1) IONA trial primary outcome (coronary heart disease (CHD) death, non-fatal myocardial infarction, or hospital admission for cardiac chest pain); (2) acute coronary syndrome (CHD death, non-fatal myocardial infarction, or unstable angina); and (3) event-free survivors at the end of the trial. The net cost for each additional IONA trial end point averted was -5 pounds sterling (-7 euros). The net cost for each case of acute coronary syndrome averted was -8 pounds sterling (-12 euros). The net cost for each event-free survivor was -5 pounds sterling (-7 euros). These figures are based on gastrointestinal eve...Continue Reading

References

Jun 1, 1984·British Heart Journal·A G ShaperP W Macfarlane
Feb 1, 1995·British Heart Journal·M M GandhiD A Wood
Jun 20, 1996·The American Journal of Cardiology·P HjemdahlN Rehnqvist
Aug 14, 1999·Journal of Internal Medicine·N ZethraeusB Jönsson
Jun 7, 2002·The New England Journal of Medicine·Jean-Michel GaspozLee Goldman
Nov 16, 2002·Heart·J L Y LiuM Rayner

❮ Previous
Next ❯

Citations

Jun 2, 2010·PharmacoEconomics·Renée J G Arnold, Sean Ekins
Aug 11, 2006·Current Opinion in Cardiology·Ami B Bhatt, Peter H Stone
Mar 21, 2012·The Canadian Journal of Cardiology·Michael McGillionUNKNOWN Canadian Pain Society
Nov 13, 2007·Drug Discovery Today·Renée J Goldberg Arnold
Dec 14, 2019·Indian Journal of Pharmacology·Lamiaa Ahmed Ahmed
Dec 23, 2020·Advances in Therapy·Kevin ChengRanil De Silva

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.